LAVAL, Que. – Valeant Pharmaceuticals International, Inc. (TSX:VRX) has a friendly deal to acquire Solta Medical, Inc. a California-based company that makes medical devices used in cosmetic surgery procedures.
Breaking news from Canada and around the world
sent to your email, as it happens.
The Montreal-area company’s offer of US$2.92 per share for all of Solta’s stock is valued at US$250 million, a 40 per cent premium to Friday’s closing price on Nasdaq.
Solta’s board of directors supports offer, which requires that Valeant gets at least a majority of Solta’s shares.
More on Canada
Comments